Reuters -- Astellas Pharma, Japan’s second-largest drugmaker, said the U.S. Food and Drug Administration has approved a six-month extension of patent protection for its prostate drug Flomax under its pediatric exclusivity rules.
Reuters -- Astellas Pharma, Japan’s second-largest drugmaker, said the U.S. Food and Drug Administration has approved a six-month extension of patent protection for its prostate drug Flomax under its pediatric exclusivity rules.
